HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Practice guidelines of the use of bisphosphonates in solid tumours with bone metastases and in multiple myeloma].

Abstract
Bisphosphonates are indicated for the treatment of bone lesions in patients with solid tumours or multiple myeloma. Bisphosphonates have proven their effectiveness in reducing the number of bone complications (hypercalcemia, pain, disease-related fractures, spinal cord compression) and delaying their occurrence in patients with bone tumours; they have also been shown to reduce the need for bone surgery and palliative or pain-relieving radiotherapy in these patients. International recommendations for the treatment of bone lesions related to malignant solid tumours and multiple myeloma have been established. We have elaborated clinical practice guidelines on the use of bisphosphonates to assist treatment decision-making in bone oncology. The guide contains decision trees and tables with information to guide pre-treatment evaluation and patient follow-up, as well as indications and conditions of use of bisphosphonates. In 2007, the regional cancer network of Rhône-Alpes, ONCORA, formed a working group (GIP ONCORA) to elaborate the guideline. The final version was then discussed and adopted at a plenary session in July 2009, during a collaborative workshop on supportive care recommendations organized by ONCORA and the regional cancer network of Lorraine.
AuthorsJ F Brantus, C Roemer-Becuwe, P Cony-Makhoul, S Salino, A Fontana, P Debourdeau, T Thomas, J P Guastalla, H Ghesquieres, C Sebban, M Pavic, P Collet, J P Larbre, S Martinon, F Brocard, A G Bodard, G Blanc, V Balestrière, B Favier, F Farsi, I Krakowski, P Biron, Réseau régional Rhône-Alpin (GIP ONCORA)
JournalLa Revue de medecine interne (Rev Med Interne) Vol. 32 Issue 8 Pg. 494-505 (Aug 2011) ISSN: 1768-3122 [Electronic] France
Vernacular TitleGuide de recommandations d'utilisation des bisphosphonates dans les lésions osseuses malignes des tumeurs solides et du myélome multiple.
PMID21376431 (Publication Type: English Abstract, Journal Article, Practice Guideline)
CopyrightCopyright © 2011 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
Topics
  • Bone Density Conservation Agents (therapeutic use)
  • Bone Neoplasms (drug therapy, secondary)
  • Decision Trees
  • Diphosphonates (therapeutic use)
  • Humans
  • Multiple Myeloma (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: